{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:52:51Z","timestamp":1793249571527,"version":"4.5.0"},"reference-count":79,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:sec id=\"ab-nrv260001-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Glioblastoma (GBM) remains a disease with high mortality despite treatment with maximal safe surgical resection, radiation, and temozolomide. Standard of care for GBM has remained unchanged for decades. Gene therapies using both viral and nonviral platforms have the potential to significantly improve outcomes but have faced challenges related to delivery, intratumoral heterogeneity, and immunologic limitations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-nrv260001-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>This review discusses the most recent progress in genetic therapies for gliomas, with a focus on clinical platforms and those nearing clinical translation. Oncolytic and nonlytic replicating viral therapies remain the most clinically advanced, with adeno-associated virus and nonviral systems approaching clinical translation. Treatment efficacy has been variable across trials, platforms, and payloads. Oncolytic herpes simplex virus (G47\u0394, teserpaturev) has been conditionally approved for the treatment of gliomas in Japan, while next-generation constructs show a potential association between immunologic activation and survival. Common challenges include the verification and quantification of delivery efficiency, the balance between antivector and antitumor immunity, appropriately designed clinical trials, relevant modeling of vector behavior in the preclinical setting, regulatory clearance, and manufacturing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-nrv260001-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Understanding the potential and limitations of gene therapies for gliomas is vital in navigating the path forward for these promising therapies. The future of these treatments will focus on improved clinical trial design with rapid confirmation and tracking of delivery, biomarker feedback and assay optimization, and combination strategies. A focus on delivery platform development can compress iteration cycles and lead to therapeutic benefit for patients with gliomas and other solid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaneurol.2026.2131","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:00:17Z","timestamp":1783954817000},"page":"808","source":"Crossref","is-referenced-by-count":2,"title":["Recent Advances and Future Prospects in Gene Delivery Platforms for Glioblastoma"],"prefix":"10.1001","volume":"83","author":[{"given":"Alexander F.","family":"Haddad","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rithvik","family":"Ramesh","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Armando Pe\u00f1a","family":"Agudelo","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Michigan Medical School, Ann Arbor"},{"name":"Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Salha","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav","family":"Prakash","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya R.","family":"Aghi","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Trippett","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Castro","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Michigan Medical School, Ann Arbor"},{"name":"Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish K.","family":"Aghi","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10426","key":"nrv260001r1","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S0140-6736(23)01952-9","article-title":"A new age of precision gene therapy.","volume":"403","author":"Schambach","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"nrv260001r2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrg2775","article-title":"Synthetic biology: applications come of age.","volume":"11","author":"Khalil","year":"2010","journal-title":"Nat Rev Genet"},{"issue":"7","key":"nrv260001r3","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors.","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"10","key":"nrv260001r4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","article-title":"AAV-based in vivo gene therapy for neurological disorders.","volume":"22","author":"Ling","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"nrv260001r5","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1016\/j.ymthe.2022.08.003","article-title":"Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson\u2019s disease.","volume":"30","author":"Rocco","year":"2022","journal-title":"Mol Ther"},{"issue":"12","key":"nrv260001r6","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020.","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"issue":"4","key":"nrv260001r7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/neuonc\/noac198","article-title":"National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"issue":"3","key":"nrv260001r8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1215\/15228517-2008-093","article-title":"Quality of life in adults with brain tumors: current knowledge and future directions.","volume":"11","author":"Liu","year":"2009","journal-title":"Neuro Oncol"},{"issue":"10","key":"nrv260001r9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"5007","key":"nrv260001r10","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1126\/science.1851332","article-title":"Experimental therapy of human glioma by means of a genetically engineered virus mutant.","volume":"252","author":"Martuza","year":"1991","journal-title":"Science"},{"issue":"12","key":"nrv260001r11","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/nm1297-1354","article-title":"Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.","volume":"3","author":"Ram","year":"1997","journal-title":"Nat Med"},{"issue":"505","key":"nrv260001r12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw5680","article-title":"Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial.","volume":"11","author":"Chiocca","year":"2019","journal-title":"Sci Transl Med"},{"issue":"4","key":"nrv260001r13","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.18632\/oncotarget.6737","article-title":"Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma.","volume":"7","author":"Ji","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"nrv260001r14","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/neuonc\/now002","article-title":"Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.","volume":"18","author":"Wheeler","year":"2016","journal-title":"Neuro Oncol"},{"key":"nrv260001r15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/B978-0-323-90120-8.00009-5","article-title":"Cell and gene therapy in neuro-oncology.","volume":"205","author":"Varela","year":"2024","journal-title":"Handb Clin Neurol"},{"issue":"10","key":"nrv260001r16","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1016\/j.ymthe.2023.08.009","article-title":"Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: translational developments from rodents to glioma patients.","volume":"31","author":"Faisal","year":"2023","journal-title":"Mol Ther"},{"issue":"9","key":"nrv260001r17","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/S1470-2045(23)00347-9","article-title":"Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial.","volume":"24","author":"Umemura","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10","key":"nrv260001r18","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1093\/neuonc\/noaf079","article-title":"A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma.","volume":"27","author":"Wen","year":"2025","journal-title":"Neuro Oncol"},{"issue":"6","key":"nrv260001r19","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial.","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat Med"},{"issue":"14","key":"nrv260001r20","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma.","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"nrv260001r21","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","article-title":"Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.","volume":"22","author":"Fares","year":"2021","journal-title":"Lancet Oncol"},{"key":"nrv260001r22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1146\/annurev-cancerbio-030617-050254","article-title":"Oncolytic herpes simplex viruses as a paradigm for the treatment of cancer.","volume":"2","author":"Bommareddy","year":"2018","journal-title":"Annu Rev Cancer Biol"},{"issue":"8","key":"nrv260001r23","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47? for residual or recurrent glioblastoma: a phase 2 trial.","volume":"28","author":"Todo","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"nrv260001r24","doi-asserted-by":"publisher","first-page":"6396","DOI":"10.1073\/pnas.101136398","article-title":"Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.","volume":"98","author":"Todo","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7985","key":"nrv260001r25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma.","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"},{"issue":"9","key":"nrv260001r26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/14712598.2021.1902982","article-title":"Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer.","volume":"21","author":"Collins","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"nrv260001r27","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jamaoncol.2020.3161","article-title":"Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial.","volume":"6","author":"Cloughesy","year":"2020","journal-title":"JAMA Oncol"},{"key":"nrv260001r28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-72746-5","article-title":"Non-lytic viral immunotherapy induces long-term glioblastoma survival and tumor-specific immunity without eliciting an antiviral response.","author":"Haddad","year":"2026","journal-title":"Nat Commun"},{"issue":"2","key":"nrv260001r29","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus.","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med"},{"issue":"408","key":"nrv260001r30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan4220","article-title":"Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.","volume":"9","author":"Brown","year":"2017","journal-title":"Sci Transl Med"},{"issue":"9","key":"nrv260001r31","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.2174\/138920112800958896","article-title":"Attenuated oncolytic measles virus strains as cancer therapeutics.","volume":"13","author":"Msaouel","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"issue":"1","key":"nrv260001r32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41467-023-43076-7","article-title":"Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial.","volume":"15","author":"Galanis","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"nrv260001r33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases.","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"nrv260001r34","doi-asserted-by":"publisher","first-page":"931","DOI":"10.4103\/1673-5374.250570","article-title":"Characteristics and advantages of adeno-associated virus vector-mediated gene therapy for neurodegenerative diseases.","volume":"14","author":"Qu","year":"2019","journal-title":"Neural Regen Res"},{"issue":"1","key":"nrv260001r35","doi-asserted-by":"publisher","first-page":"5871","DOI":"10.1038\/s41467-024-49989-1","article-title":"Adeno-associated virus delivered CXCL9 sensitizes glioblastoma to anti-PD-1 immune checkpoint blockade.","volume":"15","author":"von Roemeling","year":"2024","journal-title":"Nat Commun"},{"issue":"16","key":"nrv260001r36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e14020","article-title":"NXL-004: a novel trans-differentiation therapy for glioblastoma treatment.","volume":"42","author":"Chen","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"nrv260001r37","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1038\/s41598-018-19825-w","article-title":"Gene therapy for human glioblastoma using neurotropic JC virus-like particles as a gene delivery vector.","volume":"8","author":"Chao","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"nrv260001r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102280","article-title":"Emerging trends in virus and virus-like particle gene therapy delivery to the brain.","volume":"35","author":"Mandalawatta","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"issue":"12","key":"nrv260001r39","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery.","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"nrv260001r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2025.106891","article-title":"Lipid nanoparticles for the treatment of glioblastoma multiforme: current status of research and clinical translation.","volume":"108","author":"Kulkarni","year":"2025","journal-title":"J Drug Deliv Sci Technol"},{"key":"nrv260001r41","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116113","article-title":"Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment.","volume":"171","author":"Zhao","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"nrv260001r42","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr9266","article-title":"Bioengineered protein nanocarrier facilitating siRNA escape from lysosomes for targeted RNAi therapy in glioblastoma.","volume":"11","author":"Jin","year":"2025","journal-title":"Sci Adv"},{"issue":"1","key":"nrv260001r43","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1038\/s41467-019-11911-5","article-title":"Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers.","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat Commun"},{"issue":"2","key":"nrv260001r44","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1021\/acsnano.8b06842","article-title":"High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme.","volume":"13","author":"Kadiyala","year":"2019","journal-title":"ACS Nano"},{"issue":"1","key":"nrv260001r45","doi-asserted-by":"publisher","first-page":"5687","DOI":"10.1038\/s41467-020-19225-7","article-title":"Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy.","volume":"11","author":"Gregory","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"nrv260001r46","doi-asserted-by":"publisher","first-page":"8729","DOI":"10.1021\/acsnano.1c07492","article-title":"Systemic delivery of an adjuvant CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy.","volume":"16","author":"Alghamri","year":"2022","journal-title":"ACS Nano"},{"issue":"6","key":"nrv260001r47","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/mt.2014.30","article-title":"Gold nanoparticles for nucleic acid delivery.","volume":"22","author":"Ding","year":"2014","journal-title":"Mol Ther"},{"issue":"1","key":"nrv260001r48","doi-asserted-by":"publisher","first-page":"14912","DOI":"10.1038\/s41598-019-50332-8","article-title":"Effect of gold nanoparticle size on their properties as contrast agents for computed tomography.","volume":"9","author":"Dong","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"nrv260001r49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062425","article-title":"Selective targeting of brain tumors with gold nanoparticle-induced radiosensitization.","volume":"8","author":"Joh","year":"2013","journal-title":"PLoS One"},{"key":"nrv260001r50","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.2147\/IJN.S238206","article-title":"Aptamer-conjugated gold nanoparticles targeting epidermal growth factor receptor variant III for the treatment of glioblastoma.","volume":"15","author":"Peng","year":"2020","journal-title":"Int J Nanomedicine"},{"issue":"584","key":"nrv260001r51","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb3945","article-title":"A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma.","volume":"13","author":"Kumthekar","year":"2021","journal-title":"Sci Transl Med"},{"issue":"2","key":"nrv260001r52","doi-asserted-by":"publisher","first-page":"372","DOI":"10.20892\/j.issn.2095-3941.2020.0524","article-title":"Gold-based nanomaterials for the treatment of brain cancer.","volume":"18","author":"Tu","year":"2021","journal-title":"Cancer Biol Med"},{"issue":"1","key":"nrv260001r53","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.34028","article-title":"Emerging recombinant oncolytic poliovirus therapies against malignant glioma: a review.","volume":"15","author":"Dighe","year":"2023","journal-title":"Cureus"},{"issue":"3","key":"nrv260001r54","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14712598.2017.1288713","article-title":"Potential and clinical translation of oncolytic measles viruses.","volume":"17","author":"Robinson","year":"2017","journal-title":"Expert Opin Biol Ther"},{"issue":"13","key":"nrv260001r55","doi-asserted-by":"publisher","DOI":"10.1128\/genomeA.00184-18","article-title":"Complete genome sequences of six measles virus strains.","volume":"6","author":"Phan","year":"2018","journal-title":"Genome Announc"},{"issue":"41","key":"nrv260001r56","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202404234","article-title":"Lipid nanoparticles: versatile drug delivery vehicles for traversing the blood brain barrier to treat brain cancer.","volume":"34","author":"Cai","year":"2024","journal-title":"Adv Funct Mater"},{"issue":"11","key":"nrv260001r57","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1093\/neuonc\/noaf162","article-title":"Lipid nanoparticle formulation for gene editing and RNA-based therapies for glioblastoma.","volume":"27","author":"Zhang","year":"2025","journal-title":"Neuro Oncol"},{"issue":"1","key":"nrv260001r58","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47? in patients with progressive glioblastoma.","volume":"13","author":"Todo","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"nrv260001r59","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1038\/s41467-024-49286-x","article-title":"Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response.","volume":"15","author":"Webb","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"nrv260001r60","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41417-021-00351-3","article-title":"Cutting both ways: the innate immune response to oncolytic virotherapy.","volume":"29","author":"Mealiea","year":"2022","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"nrv260001r61","doi-asserted-by":"publisher","first-page":"28861","DOI":"10.1038\/s41598-024-80542-8","article-title":"Effects of virus-induced immunogenic cues on oncolytic virotherapy.","volume":"14","author":"Bhatt","year":"2024","journal-title":"Sci Rep"},{"key":"nrv260001r62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113743","article-title":"Local controlled release of stabilized monoclonal antibodies.","volume":"383","author":"Chang","year":"2025","journal-title":"J Control Release"},{"issue":"5","key":"nrv260001r63","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11910-024-01338-x","article-title":"Strategies to improve drug delivery across the blood-brain barrier for glioblastoma.","volume":"24","author":"Narsinh","year":"2024","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"nrv260001r64","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11060-023-04536-8","article-title":"Understanding current experimental models of glioblastoma-brain microenvironment interactions.","volume":"166","author":"Yadav","year":"2024","journal-title":"J Neurooncol"},{"issue":"1","key":"nrv260001r65","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdab100","article-title":"Mouse models of glioblastoma for the evaluation of novel therapeutic strategies.","volume":"3","author":"Haddad","year":"2021","journal-title":"Neurooncol Adv"},{"issue":"23","key":"nrv260001r66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2118697119","article-title":"A predictive microfluidic model of human glioblastoma to assess trafficking of blood-brain barrier-penetrant nanoparticles.","volume":"119","author":"Straehla","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"nrv260001r67","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? a critical assessment of existing clinical data.","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro Oncol"},{"issue":"14","key":"nrv260001r68","doi-asserted-by":"publisher","first-page":"6361","DOI":"10.7150\/thno.46468","article-title":"Comparative study of preclinical mouse models of high-grade glioma for nanomedicine research: the importance of reproducing blood-brain barrier heterogeneity.","volume":"10","author":"Brighi","year":"2020","journal-title":"Theranostics"},{"issue":"11","key":"nrv260001r69","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/acs.molpharmaceut.5c00609","article-title":"Altered abundance of barrier-related proteins in brain microvascular endothelial cells of the GL261 mouse model of glioblastoma.","volume":"22","author":"Koehn","year":"2025","journal-title":"Mol Pharm"},{"issue":"2","key":"nrv260001r70","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11060-014-1514-2","article-title":"In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma animal models.","volume":"119","author":"Leten","year":"2014","journal-title":"J Neurooncol"},{"issue":"819","key":"nrv260001r71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adv2881","article-title":"Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses.","volume":"17","author":"Ling","year":"2025","journal-title":"Sci Transl Med"},{"issue":"6731","key":"nrv260001r72","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm5214","article-title":"Distinct myeloid-derived suppressor cell populations in human glioblastoma.","volume":"387","author":"Jackson","year":"2025","journal-title":"Science"},{"issue":"12","key":"nrv260001r73","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1093\/neuonc\/noae149","article-title":"Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma.","volume":"26","author":"Montoya","year":"2024","journal-title":"Neuro Oncol"},{"issue":"1","key":"nrv260001r74","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00701-024-05931-4","article-title":"Efficacy and safety of cysto-ventricular catheter implantation for space-occupying cysts arising from glioma and brain metastasis: a retrospective study.","volume":"166","author":"Niedermeyer","year":"2024","journal-title":"Acta Neurochir (Wien)"},{"issue":"559","key":"nrv260001r75","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors.","volume":"12","author":"Park","year":"2020","journal-title":"Sci Transl Med"},{"key":"nrv260001r76","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.omto.2020.03.018","article-title":"Viral delivery of CAR targets to solid tumors enables effective cell therapy.","volume":"17","author":"Aalipour","year":"2020","journal-title":"Mol Ther Oncolytics"},{"issue":"12","key":"nrv260001r77","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202407262","article-title":"CD47 knock-out using CRISPR-Cas9 RNA lipid nanocarriers results in reduced mesenchymal glioblastoma growth in vivo.","volume":"12","author":"Rouatbi","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"nrv260001r78","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1038\/s41598-022-06430-1","article-title":"Dual-sgRNA CRISPR\/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization.","volume":"12","author":"Fierro","year":"2022","journal-title":"Sci Rep"},{"issue":"4","key":"nrv260001r79","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u00df inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors.","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2851424\/jamaneurology_haddad_2026_rv_260001_1786107774.31649.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:00:31Z","timestamp":1786374031000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2851424"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":79,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2026.2131","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}